This page shows the latest balugrastim news and features for those working in and with pharma, biotech and healthcare.
tilmanocept) for the delineation and localisation of sentinel lymph nodes; and Teva's Egranli (balugrastim) to treat chemotherapy-induced neutropenia.
FDA requests more data for balugrastim. Teva said this week it is "assessing its options" after withdrawing the US drug filing for long-acting white cell stimulator balugrastim. ... The FDA has agreed to work with Teva in designing any additional studies
Teva's biologics pipeline also includes reslizumab, a monoclonal antibody targeting interleukin-5 (IL-5) in phase III for moderate-to-severe asthma, and an albumin-fused G-CSF called balugrastim
More from news
Approximately 1 fully matching, plus 2 partially matching documents found.
We are the largest independent healthcare market research and consulting agencies in the world. Trusted partner to the global pharmaceutical...